MaxCyte Inc
Research MaxCyte Inc (MXCT) on Bullrun: market cap USD 105.60M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMXCT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Market capUSD 105.60M
- Financial periodQ2 2026
- RevenueUSD 7.27M
- Net income-USD 8.87M
- Free cash flow-USD 4.72M
- Gross margin77.0%
Valuation Snapshot
latest market cap is USD 105.60M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 20.96M | -USD 44.63M | -USD 36.18M | 127.9% | -0.42 | USD 20.07M | USD 17.94M | USD 171.49M |
| FY2024 | USD 22.22M | -USD 41.06M | -USD 29.26M | 141.9% | -0.39 | USD 27.88M | USD 18.03M | USD 206.25M |
| FY2023 | USD 19.50M | -USD 37.92M | -USD 25.39M | 187.4% | -0.37 | USD 46.51M | USD 18.74M | USD 232.17M |
| FY2022 | USD 28.75M | -USD 23.57M | -USD 33.26M | 136.2% | -0.23 | USD 11.07M | USD 16.10M | USD 253.97M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 105.60M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 165.52M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 439.76M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 486.81M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 557.18M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.03B | n/a | n/a | n/a |
About MaxCyte Inc
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is MaxCyte Inc's market cap?
MaxCyte Inc's market capitalization is USD 105.60M.
What does MaxCyte Inc do?
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.